Unfortunately, the central nervous system (CNS) remains a sanctuary site for crizotinib, and patients have a high risk of developing brain metastases, a common event in NSCLC observed in 60% of “ALK-positive” patients, resulting in significant morbidity and poor survival prognosis [5,6,7]. Here, ALK is linked to non-small cell lung carcinoma.